Form 8-K - Current report:
SEC Accession No. 0001628280-21-025612
Filing Date
2021-12-27
Accepted
2021-12-27 17:07:16
Documents
15
Period of Report
2021-12-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20211227.htm   iXBRL 8-K 48094
2 EX-1.2 ex12amendmentno1toatmsales.htm EX-1.2 31332
3 EX-5.1 a00exhibit51.htm EX-5.1 19142
7 GRAPHIC image_0.jpg GRAPHIC 278098
  Complete submission text file 0001628280-21-025612.txt   633559

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20211227.xsd EX-101.SCH 2011
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20211227_lab.xml EX-101.LAB 24137
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20211227_pre.xml EX-101.PRE 12609
9 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20211227_htm.xml XML 11025
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 211521225
SIC: 2834 Pharmaceutical Preparations